Prelude Therapeutics Inc. — Q1 2021 Form 10-Q
Reporting period: Three months ended March 31, 2021. Financial statements are unaudited. Prelude is a clinical-stage precision oncology company with no product revenue to date.
Financial results and liquidity
| Metric | Q1 2021 | Q1 2020 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $16.5 million | $8.5 million |
| General and administrative expense | $5.5 million | $1.2 million |
| Total operating expenses | $22.0 million | $9.7 million |
| Net loss | $21.3 million | $9.5 million |
| Net loss per share, basic and diluted | $0.47 | $5.12 |
| Cash used in operating activities | $16.1 million | $9.9 million |
| Cash used in investing activities | $1.0 million | $0.1 million |
| Cash provided by financing activities | $161.8 million | $29.8 million |
- Cash and cash equivalents were $363.0 million at March 31, 2021, versus $218.3 million at December 31, 2020. Management expects available cash to fund operating expenses and capital expenditures into 2023, based on assumptions that may prove inaccurate.
- Current assets were $365.0 million and current liabilities were $12.4 million. Total liabilities were $13.3 million, including $2.2 million of operating lease liabilities. The filing reports no credit facility or committed sources of capital.
- Accumulated deficit was $128.7 million. Profitability and operating margins are not meaningful because the company has no revenue and is loss-making.
- January’s public offering of 2.875 million common shares at $60 per share generated $161.4 million net proceeds. Q1 financing cash flows also included $0.4 million from stock-option exercises.
Changes versus prior comparable period
- Net loss increased by $11.8 million year over year. R&D expense rose $7.9 million, principally due to clinical-trial and manufacturing costs for PRT543 and PRT811, initiation of the oral PRT1419 trial, and preparation for IV PRT1419 development.
- G&A expense increased $4.3 million, primarily from higher personnel and professional fees, including costs of operating as a public company.
- Operating cash use increased to $16.1 million from $9.9 million. The January common-stock offering drove financing cash inflows and the increase in cash reserves.
- Loss per share is not directly comparable: weighted-average shares rose to 45.1 million from 1.9 million following the company’s transition from private to public and changes in its capital structure.
Outlook, management commentary, and risks
- Management expects significant R&D and G&A expenses and operating losses to continue as programs advance; the company does not expect product-sales revenue in the foreseeable future. Additional funding may be needed after the projected cash runway, through equity, debt, collaborations, alliances, or licensing.
- Pipeline milestones: PRT543 Phase 1 enrollment was complete in the adenoid cystic carcinoma expansion cohort; additional expansion cohorts were enrolling. Initial Phase 1 data were anticipated in the second half of 2021. PRT811 Phase 1 expansion enrollment was expected by mid-2021, with initial data anticipated by year-end. Oral PRT1419 Phase 1 enrollment had begun; expansion and combination cohorts were expected in the second half of 2021. The FDA cleared an IV PRT1419 IND in March, with a Phase 1 trial expected to begin in the coming months.
- Management reported early clinical activity: an ongoing confirmed complete response in a patient receiving PRT543, and a PRT811-treated glioblastoma patient’s tumor regression increased to 77% from baseline at week 18, described as a partial response under RANO criteria. These are early-stage findings and do not establish efficacy or predict later-trial outcomes.
- COVID-19 had caused limited delays in some site initiations and patient participation or enrollment; management said lead programs and research remained on track, while noting potential for further disruption and increased costs.
- Safety remains a development risk. PRT543 had related grade 4 thrombocytopenia at the highest dose, reversible after a drug holiday and dose reduction. The filing cautions that additional or more serious adverse events may emerge in larger or later trials.
- Key risks include clinical failure or delays, patient-enrollment challenges, reliance on third-party CROs and manufacturers, competition, regulatory uncertainty, intellectual-property challenges, and the need for future financing. The company stated it was not party to legal proceedings that management considered likely to have a material adverse effect.
- Other notable items: the company adopted ASC 842 lease accounting on January 1, 2021, recognizing a right-of-use asset and lease liabilities; adoption did not materially affect results or cash flows. Management reported disclosure controls effective at a reasonable-assurance level and no material quarterly changes in internal control over financial reporting.
Investor facts to verify
- Whether the projected cash runway into 2023 remains achievable as trial scope, enrollment, and development costs change.
- Subsequent clinical data for PRT543, PRT811, and PRT1419, including durability, patient numbers, safety, and whether early responses are confirmed in broader cohorts.
- Actual timing and results of the planned trial expansions and the IV PRT1419 Phase 1 trial.
- Future R&D spending, cash burn, and any financing, collaboration, or licensing transactions, including potential dilution or rights granted.
- Effects of COVID-19 or other operational constraints on trial enrollment, sites, vendors, manufacturing, and timelines.